Pharmacometabolomics: Implications for clinical pharmacology and systems pharmacology

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 2, 2014, Pages 154-167

  Kaddurah Daouk, Rima ^a,b   Weinshilboum, R M ^c,d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAMINOPHEN; ANIMALS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY; DRUG-INDUCED LIVER INJURY; GASTROINTESTINAL TRACT; HUMANS; METABOLOMICS; MICROBIOTA; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; SYSTEMS BIOLOGY; TREATMENT OUTCOME;

EID: 84893763297     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.217     Document Type: Article

References (80)

1. Vesell, E.S. & Page, J.G. Genetic control of drug levels in man: Antipyrine. Science 161, 72-73 (1968).
2. Vesell, E.S. & Page, J.G. Genetic control of dicumarol levels in man. J. Clin. Invest. 47, 2657-2663 (1968).
3. Weinshilboum, R. & Wang, L. Pharmacogenomics: Bench to bedside. Nat. Rev. Drug Discov. 3, 739-748 (2004).
4. Weinshilboum, R.M. & Wang, L. Pharmacogenetics and pharmacogenomics: Development, science, and translation. Annu. Rev. Genomics Hum. Genet. 7, 223-245 (2006).
5. Wang, L., McLeod, H.L. & Weinshilboum, R.M. Genomics and drug response. N. Engl. J. Med. 364, 1144-1153 (2011).
6. Kaddurah-Daouk, R., Kristal, B.S. & Weinshilboum, R.M. Metabolomics: A global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol. 48, 653-683 (2008).
7. Kaddurah-Daouk, R. et al. Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study. Metabolomics 6, 191-201 (2010).
8. Trupp, M. et al. Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment. PLoS ONE 7, e38386 (2012).
9. Kaddurah-Daouk, R. et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: A proof of concept. Transl. Psychiatry 1, (2011).
10. Kaddurah-Daouk, R. et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl. Psychiatry 3, e223 (2013).
11. Zhu, H. et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder -possible role for methoxyindole pathway. PLoS One. 8, e68283 (2013).
12. Ji, Y. et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: Pharmacometabolomics- informed pharmacogenomics. Clin. Pharmacol. Ther. 89, 97-104 (2011).
13. Abo, R. et al. Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: Selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet. Genomics 22, 247-253 (2012).
14. Yerges-Armstrong, L.M. et al. Purine pathway implicated in mechanism of resistance to aspirin therapy: Pharmacometabolomics-informed pharmacogenomics. Clin. Pharmacol. Ther. 94, 525-532 (2013).
15. Wikoff, W.R. et al.; Pharmacometabolomics Research Network. Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS ONE 8, e57639 (2013).
16. Nicholson, J.K., Wilson, I.D. & Lindon, J.C. Pharmacometabonomics as an effector for personalized medicine. Pharmacogenomics 12, 103-111 (2011).
17. Everett, J.R., Loo, R.L. & Pullen, F.S. Pharmacometabonomics and personalized medicine. Ann. Clin. Biochem. 50, 523-545 (2013).
18. Robertson, D.G., Watkins, P.B. & Reily, M.D. Metabolomics in toxicology: Preclinical and clinical applications. Toxicol. Sci. 120 (suppl. 1), S146-S170 (2011).
19. Kaddurah-Daouk, R. & Krishnan, K.R. Metabolomics: A global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 34, 173-186 (2009).
20. Patti, G.J., Yanes, O. & Siuzdak, G. Innovation: Metabolomics: The apogee of the omics trilogy. Nat. Rev. Mol. Cell Biol. 13, 263-269 (2012).
21. van der Greef, J., Hankemeier, T. & McBurney, R.N. Metabolomics-based systems biology and personalized medicine: Moving towards n = 1 clinical trials Pharmacogenomics 7, 1087-1094 (2006).
22. Holmes, E., Wilson, I.D. & Nicholson, J.K. Metabolic phenotyping in health and disease. Cell 134, 714-717 (2008).
23. Wikoff, W.R. et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA 106, 3698-3703 (2009).
24. Xie, G., Zhang, S., Zheng, X. & Jia, W. Metabolomics approaches for characterizing metabolic interactions between host and its commensal microbes. Electrophoresis 34, 2787-2798 (2013).
25. Kristal, B.S., Shurubor, Y.I., Kaddurah-Daouk, R. & Matson, W.R. Highperformance liquid chromatography separations coupled with coulometric electrode array detectors: A unique approach to metabolomics. Methods Mol. Biol. 358, 159-174 (2007).
26. Rozen, S. et al. Metabolomic analysis and signatures in motor neuron disease. Metabolomics 1, 101-108 (2005).
27. Yao, J.K. et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol. Psychiatry 15, 938-953 (2010).
28. Yao, J.K. et al. Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. PLoS ONE 5, e9508 (2010).
29. Yao, J.K. et al. Associations between purine metabolites and clinical symptoms in schizophrenia. PLoS ONE 7, e42165 (2012).
30. Condray, R. et al. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int. J. Neuropsychopharmacol. 14, 756-767 (2011).
31. Patkar, A.A. et al. Alterations in tryptophan and purine metabolism in cocaine addiction: A metabolomic study. Psychopharmacology (Berl.) 206, 479-489 (2009).
32. Mannelli, P., Patkar, A., Rozen, S., Matson, W., Krishnan, R. & Kaddurah-Daouk, R. Opioid use affects antioxidant activity and purine metabolism: Preliminary results. Hum. Psychopharmacol. 24, 666-675 (2009).
33. Kaddurah-Daouk, R. et al.; Pharmacometabolomics Research Network. Alterations in metabolic pathways and networks in Alzheimer's disease. Transl. Psychiatry 3, e244 (2013).
34. Theodoridis, G., Gika, H.G. & Wilson, I.D. Mass spectrometry-based holistic analytical approaches for metabolite profiling in systems biology studies. Mass. Spectrom. Rev. 30, 884-906 (2011).
35. Theodoridis, G.A., Gika, H.G., Want, E.J. & Wilson, I.D. Liquid chromatographymass spectrometry based global metabolite profiling: A review. Anal. Chim. Acta 711, 7-16 (2012).
36. Lindon, J.C. & Nicholson, J.K. Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu. Rev. Anal. Chem. (Palo Alto Calif.) 1, 45-69 (2008).
37. Beckonert, O. et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2, 2692-2703 (2007).
38. F an, T.W. et al. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol. Cancer 8, 41 (2009).
39. Bousamra, M. et al. Clinical aspects of metabolomics. In The Handbook of Metabolomics. Chap. Vol. 17. (eds. Whei-Mei Fan, T., Lane, A.N. & Higashi, R.M.) (Humana Press, Totowa, NJ, 2012).
40. Lane, A.N. et al. Clinical applications of stable isotope-resolved metabolomics (sirm) in non-small cell lung cancer. Omics. 15, 173-182 (2011).
41. F an, T.W., Lorkiewicz, P.K., Sellers, K., Moseley, H.N., Higashi, R.M. & Lane, A.N. Stable isotope-resolved metabolomics and applications for drug development. Pharmacol. Ther. 133, 366-391 (2012).
42. F an, T.W. et al. Stable isotope-resolved metabolomic analysis of lithium effects on glial-neuronal metabolism and interactions. Metabolomics 6, 165-179 (2010).
43. Thornburg, J.M. et al. Targeting aspartate aminotransferase in breast cancer. Breast Cancer Res. 10, R84 (2008).
44. Krauss, R.M., Zhu, H. & Kaddurah-Daouk, R. Pharmacometabolomics of statin response. Clin. Pharmacol. Ther. 94, 562-565 (2013).
45. Lewis, J.P., Yerges-Armstrong, L.M., Ellero-Simatos, S., Georgiades, A., Kaddurah-Daouk, R. & Hankemeier, T. Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy. Clin. Pharmacol. Ther. 94, 570-573 (2013).
46. Kessler, R.C. et al.; National Comorbidity Survey Replication. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 289, 3095-3105 (2003).
47. Schildkraut, J.J. Neuropsychopharmacology and the affective disorders. (Third of three parts). N. Engl. J. Med. 281, 302-8 concl (1969).
48. Trivedi, M.H. et al.; STARD Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STARD: Implications for clinical practice. Am. J. Psychiatry 163, 28-40 (2006).
49. Baker, M., Dorzab, J., Winokur, G. & Cadoret, R. Depressive disease. Evidence favoring polygenic inheritance based on an analysis of ancestral cases. Arch. Gen. Psychiatry 27, 320-327 (1972).
50. Cichon, S. et al. Genomewide association studies: History, rationale, and prospects for psychiatric disorders. Am. J. Psychiatry 166, 540-556 (2009).
51. Wray, N.R. et al. Genome-wide association study of major depressive disorder: New results, meta-analysis, and lessons learned. Mol. Psychiatry 17, 36-48 (2012).
52. Kohli, M.A. et al. The neuronal transporter gene SLC6A15 confers risk to major depression. Neuron 70, 252-265 (2011).
53. Garriock, H.A. et al. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry 67, 133-138 (2010).
54. Ising, M. et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch. Gen. Psychiatry 66, 966-975 (2009).
55. Uher, R. et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry 167, 555-564 (2010).
56. Quinones, M.P. & Kaddurah-Daouk, R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis. 35, 165-176 (2009).
57. Paige, L.A., Mitchell, M.W., Krishnan, K.R., Kaddurah-Daouk, R. & Steffens, D.C. A preliminary metabolomic analysis of older adults with and without depression. Int. J. Geriatr. Psychiatry 22, 418-423 (2007).
58. Steffens, D.C. et al. Metabolomic differences in heart failure patients with and without major depression. J. Geriatr. Psychiatry Neurol. 23, 138-146 (2010).
59. Kaddurah-Daouk, R. et al. Cerebrospinal fluid metabolome in mood disorders. Science Reports. 2, 667 (2012).
60. Jablensky, A. et al. Schizophrenia: Manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol. Med. Monogr. Suppl. 20, 1-97 (1992).
61. Horrobin, D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 30, 193-208 (1998).
62. Mahadik, S.Y.J. Phospholipids in schizophrenia. 117-135 (American Psychiatric Publishing, Arlington, VA, 2006).
63. American Diabetes Association (ADA) Consensus Development Conference, 2004.
64. Kaddurah-Daouk, R. et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol. Psychiatry 12, 934-945 (2007).
65. Keun, H.C. et al. Serum molecular signatures of weight change during early breast cancer chemotherapy. Clin. Cancer Res. 15, 6716-6723 (2009).
66. Phapale, P.B. et al. An integrative approach for identifying a metabolic phenotype predictive of individualized pharmacokinetics of tacrolimus. Clin. Pharmacol. Ther. 87, 426-436 (2010).
67. Li, H. et al. Pharmacometabonomic phenotyping reveals different responses to xenobiotic intervention in rats. J. Proteome Res. 6, 1364-1370 (2007).
68. Cavill, R. et al. Consensus-phenotype integration of transcriptomic and metabolomic data implies a role for metabolism in the chemosensitivity of tumour cells. PLoS Comput. Biol. 7, e1001113 (2011).
69. Kwon, H.N. et al. Predicting idiopathic toxicity of cisplatin by a pharmacometabonomic approach. Kidney Int. 79, 529-537 (2011).
70. Cunningham, K. et al. Pharmacometabonomic characterization of xenobiotic and endogenous metabolic phenotypes that account for inter-individual variation in isoniazid-induced toxicological response. J. Proteome Res. 11, 4630-4642 (2012).
71. Coen, M. et al. Pharmacometabonomic investigation of dynamic metabolic phenotypes associated with variability in response to galactosamine hepatotoxicity. J. Proteome Res. 11, 2427-2440 (2012).
72. Liu, L. et al. Prediction of the pharmacokinetic parameters of triptolide in rats based on endogenous molecules in pre-dose baseline serum. PLoS ONE 7, e43389 (2012).
73. Ji, Y. et al. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: Genome-wide associations and functional genomics. Pharmacogenomics J. 13, 456-463 (2013).
74. Rush, A.J. et al.; STAR D Investigators Group. Sequenced treatment alternatives to relieve depression (STARD): Rationale and design. Control. Clin. Trials 25, 119-142 (2004).
75. The 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature. 467, 1061-1073 (2010).
76. Clayton, T.A. et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077 (2006).
77. Clayton, T.A., Baker, D., Lindon, J.C., Everett, J.R. & Nicholson, J.K. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc. Natl. Acad. Sci. USA 106, 14728-14733 (2009).
78. Winnike, J.H., Li, Z., Wright, F.A., Macdonald, J.M., O'Connell, T.M. & Watkins, P.B. Use of pharmaco-metabonomics for early prediction of acetaminopheninduced hepatotoxicity in humans. Clin. Pharmacol. Ther. 88, 45-51 (2010).
79. Kaddurah-Daouk, R. et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS ONE 6, e25482 (2011).
80. Berg, J.M., Rogers, M.E. & Lyster, P.M. Systems biology and pharmacology. Clin. Pharmacol. Ther. 88, 17-19 (2010).